MAPT and Alzheimer disease: In our current NLRP3-deficient tau mice, the potential reduction of IL-1β secretion and the improvement of pericyte resistance to inflammatory challenges cannot be distinguished in case NLRP3 inhibition leads to AD prevention; (2) we missed the functional detection of blood flow in the brain of tau-transgenic mice.